The businesses entered into an agreement Nov. 14 to combine, and the resulting company will have an estimated pro-forma enterprise value of $482 million. The transaction is expected to close in early 2022.
Chris Walsh, Accelus CEO and co-founder, will become CEO of the combined company. He has 25 years of experience in the medtech industry with past roles at Stryker and NuVasive.
CHP Merger Corp. is a special purpose acquisition vehicle formed by an affiliate of private equity firm Concord Health Partners.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
